Long-term data of multiple sclerosis treatment with ocrelizumab - eficacy, safety and clinical experience

2021 ◽  
Vol 22 (6) ◽  
pp. 477-480
Author(s):  
Matouš Rous ◽  
Zuzana Rous
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Experience ◽  
Term Data ◽  
Multiple Sclerosis Treatment

scholarly journals Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lisa-Marie Ohle ◽  
David Ellenberger ◽  
Peter Flachenecker ◽  
Tim Friede ◽  
Judith Haas ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Sociodemographic Factors ◽  
Healthcare Research ◽  
Structure Design ◽  
Data Repository ◽  
Research Projects ◽  
Real World Data ◽  
Data Repositories ◽  
Term Data

AbstractIn 2001, the German Multiple Sclerosis Society, facing lack of data, founded the German MS Registry (GMSR) as a long-term data repository for MS healthcare research. By the establishment of a network of participating neurological centres of different healthcare sectors across Germany, GMSR provides observational real-world data on long-term disease progression, sociodemographic factors, treatment and the healthcare status of people with MS. This paper aims to illustrate the framework of the GMSR. Structure, design and data quality processes as well as collaborations of the GMSR are presented. The registry’s dataset, status and results are discussed. As of 08 January 2021, 187 centres from different healthcare sectors participate in the GMSR. Following its infrastructure and dataset specification upgrades in 2014, more than 196,000 visits have been recorded relating to more than 33,000 persons with MS (PwMS). The GMSR enables monitoring of PwMS in Germany, supports scientific research projects, and collaborates with national and international MS data repositories and initiatives. With its recent pharmacovigilance extension, it aligns with EMA recommendations and helps to ensure early detection of therapy-related safety signals.

scholarly journals Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis

2018 ◽  
Vol 13 (1) ◽  
pp. 25 ◽  
Author(s):  
Patrick Vermersch
Keyword(s):  
Multiple Sclerosis ◽  
Oral Disease ◽  
Receptor Subtypes ◽  
Sphingosine 1 Phosphate ◽  
The Central Nervous System ◽  
S1p Receptor ◽  
Phase Ii And Iii ◽  
Receptor Modulators ◽  
Term Data

The introduction of oral disease modifying therapies has transformed the treatment landscape for patients with multiple sclerosis (MS). Fingolimod (Gilenya®, Novartis, Basel, Switzerland), the first oral therapy to be approved, has demonstrated clinical efficacy as a result of modulation of subtype 1 sphingosine-1-phosphate (S1P1) receptors. This leads to retention of lymphocytes in the lymph nodes, preventing their entry into the central nervous system. However, fingolimod can cause adverse effects as a result of its interaction with other S1P receptor subtypes, which are expressed in numerous tissues, including cardiac myocytes. More selective S1P receptor agents are currently in phase II and III clinical development. Siponimod, ozanimod, ponesimod and amiselimod have demonstrated efficacy with improved safety profiles compared with fingolimod. While more long-term data are needed, these selective S1P receptor modulators appear to be promising options for the treatment of MS and other disorders associated with autoimmunity and inflammation.

scholarly journals Tricuspid Annuloplasty: Transcatheter Approaches

2021 ◽  
Vol 23 (10) ◽  
Author(s):  
Martin Arnold ◽  
Julia Haug ◽  
Melanie Landendinger
Keyword(s):  
Clinical Experience ◽  
Tricuspid Regurgitation ◽  
Clinical Evidence ◽  
Clinical Symptoms ◽  
Published Data ◽  
Clinical Routine ◽  
Positive Effects ◽  
Tricuspid Annuloplasty ◽  
Term Data

Abstract Purpose of Review New transcatheter techniques to perform tricuspid annuloplasty are evolving and are introduced into the clinical routine. Yet, clinical experience is limited. Recent Findings Currently, 3 different techniques for tricuspid annuloplasty have been used in larger clinical cohorts. They can be divided into direct annuloplasty techniques and suture plication techniques. The largest clinical evidence is related to direct annuloplasty techniques. It has been shown that annular dimensions can be effectively reduced. This translates into an improvement of the degree of tricuspid regurgitation and improvement of clinical symptoms. Due to the newness of this type of therapy, long-term data is limited, but for one of the described techniques, published data show that the positive effects persist over a 2-year period. Summary Transcatheter approaches are safe and are able to treat tricuspid regurgitation effectively. There are still differences in the efficacy of the different techniques. Clinical experience varies among the different approaches.

Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis

2006 ◽  
Vol 13 (9) ◽  
pp. 1014-1021 ◽  
Author(s):  
G. Coppola ◽  
R. Lanzillo ◽  
C. Florio ◽  
G. Orefice ◽  
P. Vivo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Experience ◽  
Interferon Beta ◽  
Relapsing Multiple Sclerosis

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients

2015 ◽  
Vol 56 (7) ◽  
pp. 845-851 ◽  
Author(s):  
Damiano Paolicelli ◽  
Vita Direnzo ◽  
Alessia Manni ◽  
Mariangela D'Onghia ◽  
Carla Tortorella ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real Life ◽  
Real Life Setting ◽  
Multiple Sclerosis Patients ◽  
Term Data

scholarly journals A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment

Molecules ◽  
2020 ◽  
Vol 25 (21) ◽  
pp. 4930
Author(s):  
Éamon Jones ◽  
Styliani Vlachou
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Animal Models ◽  
Receptor Agonist ◽  
Double Blind ◽  
Cannabinoid Compounds ◽  
Adrenergic Receptor Agonist ◽  
Multiple Sclerosis Treatment

Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) has been approved to treat symptoms of spasticity. In animals, CBD is effective in reducing the amounts of T-cell infiltrates in the spinal cord, suggesting CBD has anti-inflammatory properties. By doing this, CBD has shown to delay symptom onset in animal models of multiple sclerosis and slow disease progression. Importantly, combinations of CBD and Δ9-THC appear more effective in treating animal models of multiple sclerosis. While CBD reduces the amounts of cell infiltrates in the spinal cord, Δ9-THC reduces scores of spasticity. In human studies, the results are less encouraging and conflict with the findings in animals. Drugs which deliver a combination of Δ9-THC and CBD in a 1:1 ratio appear to be only moderately effective in reducing spasticity scores, but appear to be almost as effective as current front-line treatments and cause less severe side effects than other treatments, such as baclofen (a GABA-B receptor agonist) and tizanidine (an α2 adrenergic receptor agonist). The findings of the studies reviewed suggest that cannabinoids may help treat neuropathic pain in pwMS as an add-on therapy to already established pain treatments. It is important to note that treatment with cannabinoid compounds may cause significant cognitive dysfunction. Long term double-blind placebo studies are greatly needed to further our understanding of the role of cannabinoids in multiple sclerosis treatment.

Sign in / Sign up

Export Citation Format

Share Document